What’s in Accuray (NASDAQ:ARAY) After Decline in Shorted Shares?

October 13, 2017 - By reb123z

 What’s in Accuray (NASDAQ:ARAY) After Decline in Shorted Shares?

Investors sentiment decreased to 1.04 in Q2 2017. Its down 0.14, from 1.18 in 2017Q1. It fall, as 23 investors sold Accuray Incorporated shares while 27 reduced holdings. 13 funds opened positions while 39 raised stakes. 62.66 million shares or 8.31% less from 68.34 million shares in 2017Q1 were reported.
3.30M are owned by Millennium Mgmt Limited Liability Com. Nomura stated it has 0% in Accuray Incorporated (NASDAQ:ARAY). Engineers Gate Manager Limited Partnership has 34,968 shares. California Pub Employees Retirement System accumulated 46,300 shares. Boston Ptnrs owns 1.86 million shares. Bnp Paribas Arbitrage Sa invested in 10,075 shares or 0% of the stock. Jacobs Levy Equity Mngmt Incorporated holds 590,807 shares. Bogle Mgmt Ltd Partnership De reported 0.09% stake. Principal Inc stated it has 0% of its portfolio in Accuray Incorporated (NASDAQ:ARAY). Barclays Pcl reported 7,805 shares. Great West Life Assurance Can reported 5,069 shares. Menlo Limited Co reported 10,000 shares. Da Davidson & invested 0% in Accuray Incorporated (NASDAQ:ARAY). Winslow Evans & Crocker Inc holds 1,648 shares. Teton Advsr holds 32,960 shares.

The stock of Accuray (NASDAQ:ARAY) registered a decrease of 3.78% in short interest. ARAY’s total short interest was 5.91M shares in October as published by FINRA. Its down 3.78% from 6.15M shares, reported previously. With 488,100 shares average volume, it will take short sellers 12 days to cover their ARAY’s short positions. The short interest to Accuray’s float is 7.68%.

The stock decreased 1.19% or $0.05 during the last trading session, reaching $4.15. About 505,209 shares traded. Accuray Incorporated (NASDAQ:ARAY) has declined 21.41% since October 13, 2016 and is downtrending. It has underperformed by 38.11% the S&P500.

Accuray Incorporated is a radiation oncology company. The company has market cap of $347.58 million. The Firm develops, makes and markets medical devices used in radiation therapy for the treatment of cancer patients. It currently has negative earnings. The Company’s products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform.

Accuray Incorporated (NASDAQ:ARAY) Ratings Coverage

Among 7 analysts covering Accuray (NASDAQ:ARAY), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. Accuray had 19 analyst reports since August 5, 2015 according to SRatingsIntel. Jefferies maintained Accuray Incorporated (NASDAQ:ARAY) on Wednesday, August 23 with “Buy” rating. The firm earned “Buy” rating on Monday, September 25 by Jefferies. The rating was maintained by RBC Capital Markets with “Hold” on Friday, September 29. RBC Capital Markets maintained Accuray Incorporated (NASDAQ:ARAY) rating on Tuesday, May 30. RBC Capital Markets has “Hold” rating and $500 target. Cowen & Co maintained the stock with “Buy” rating in Tuesday, July 18 report. The firm has “Sell” rating given on Wednesday, August 5 by Zacks. RBC Capital Markets maintained the shares of ARAY in report on Friday, January 29 with “Sector Perform” rating. As per Wednesday, August 9, the company rating was maintained by Jefferies. The stock has “Outperform” rating by Cowen & Co on Tuesday, September 13. Jefferies maintained it with “Buy” rating and $700 target in Thursday, June 29 report.

More news for Accuray Incorporated (NASDAQ:ARAY) were recently published by: Prnewswire.com, which released: “Accuray Incorporated Reports Inducement Grant Under NASDAQ Listing Rules” on October 04, 2017. Seekingalpha.com‘s article titled: “Harder And Harder To Find A Spark With Accuray” and published on August 24, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.